The ROE as of January 2025 (TTM) for Xeris Biopharma Holdings, Inc. (XERS) is 397.13%

According to Xeris Biopharma Holdings, Inc.’s latest financial reports and current stock price. The company's current ROE is 397.13%. This represents a change of 195.48% compared to the average of 134.40% of the last 4 quarters.

Xeris Biopharma Holdings, Inc. (XERS) Historical ROE (quarterly & annually)

How has XERS ROE performed in the past?

The mean historical ROE of Xeris Biopharma Holdings, Inc. over the last ten years is 13.47%. The current 397.13% ROE has changed 2.85% with respect to the historical average. Over the past ten years (40 quarters), XERS's ROE was at its highest in in the September 2021 quarter at 1.06%. The ROE was at its lowest in in the September 2023 quarter at -315.37%.

Xeris Biopharma Holdings, Inc. (XERS) ROE by Quarter and Year

Discovering the peaks and valleys of Xeris Biopharma Holdings, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Xeris Biopharma Holdings, Inc. (XERS) Average ROE

How has XERS ROE performed in the past?

The current ROE of Xeris Biopharma Holdings, Inc. (XERS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Xeris Biopharma Holdings, Inc. (XERS) ROE vs. Peers

How is XERS’s ROE compared to its peers?

Xeris Biopharma Holdings, Inc.’s ROE is greater than Protalix BioTherapeutics, Inc. (-30.89%), less than Seres Therapeutics, Inc. (60.75%), greater than Cidara Therapeutics, Inc. (-219.21%), less than ImmunityBio, Inc. (86.39%), less than Galera Therapeutics, Inc. (14.34%), greater than Mereo BioPharma Group plc (-69.11%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than PDS Biotechnology Corporation (-139.57%), greater than Inozyme Pharma, Inc. (-88.42%), greater than HOOKIPA Pharma Inc. (-49.25%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), less than eFFECTOR Therapeutics, Inc. (882.00%), greater than Elevation Oncology, Inc. (-59.73%), greater than Hepion Pharmaceuticals, Inc. (-505.74%),

Build a custom stock screener for Xeris Biopharma Holdings, Inc. (XERS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xeris Biopharma Holdings, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Xeris Biopharma Holdings, Inc. (XERS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Xeris Biopharma Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.